Literature DB >> 23141854

Minor myocardial damage is a prevalent condition in patients with acute heart failure syndromes and preserved systolic function with long-term prognostic implications: a report from the CIAST-HF (Collaborative Italo-Argentinean Study on cardiac Troponin T in Heart Failure) study.

Eduardo R Perna1, Nadia Aspromonte, Juan P Cimbaro Canella, Giuseppe Di Tano, Stella M Macin, Mauro Feola, María L Coronel, Loredano Milani, Jorge I Parras, Massimo Milli, Edgar H García, Roberto Valle.   

Abstract

BACKGROUND: Half of patients with acute heart failure syndromes (AHFS) have preserved left ventricular ejection fraction (PLVEF). In this setting, the role of minor myocardial damage (MMD), as identified by cardiac troponin T (cTnT), remains to be established. AIM: To evaluate the prevalence and long-term prognostic significance of cTnT elevations in patients with AHFS and PLVEF. PATIENTS AND METHODS: This retrospective, multicenter, collaborative study included 500 patients hospitalized for AHFS with PLVEF (ejection fraction ≥40%) between October 2000 and December 2006. Blood samples were collected within 12 hours after admission and were assayed for cTnT. MMD was defined as a cTnT value of ≥0.020 ng/mL.
RESULTS: Mean age was 73 ± 12 years, 47% were female, 38% had an ischemic etiology, and New York Heart Association (NYHA) class was 2.2 ± 0.7. Mean cTnT value was 0.149 ± 0.484 ng/mL, and cTnT was directly correlated with serum creatinine (Spearman's Rho = 0.35, P < .001) and NYHA class (0.25, P < .001). MMD was diagnosed in 220 patients (44%). Patients with MMD showed lower left ventricular ejection fraction (P < .05), higher serum creatinine (P < .001), higher prevalence of ischemic etiology and diabetes mellitus, a worse NYHA class (P < .001), and higher natriuretic peptide levels (P < .001) as compared with patients without MMD. At 6-month follow-up, overall event-free survival was 55% and 75% in patients with and without MMD (P < .001), respectively. On multivariate Cox regression analysis, only NYHA class (HR = 1.50; P = .002) and MMD (HR = 1.81; P = .001) were identified as predictors of events.
CONCLUSIONS: Increased cTnT levels were detected in approximately 50% of patients with AHFS with preserved systolic function, and were found to correlate with clinical measures of disease severity. The presence of MMD was associated with a worse long-term outcome, lending support to cTnT-based risk stratification in the setting of AHFS.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23141854     DOI: 10.1016/j.cardfail.2012.10.008

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  8 in total

Review 1.  Initial management of patients with acute heart failure.

Authors:  Gregory J Fermann; Sean P Collins
Journal:  Heart Fail Clin       Date:  2013-06-04       Impact factor: 3.179

2.  Role of Cardiac Troponin Levels in Acute Heart Failure.

Authors:  Nicholas Wettersten; Alan Maisel
Journal:  Card Fail Rev       Date:  2015-10

3.  Mineralocorticoid Receptor Antagonism in Acute Heart Failure.

Authors:  Kemar Brown; Jennifer Chee; Stella Kyung; Bicky Vettichira; Lampros Papadimitriou; Javed Butler
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-09

4.  Cardiac troponin and outcome in decompensated heart failure with preserved ejection fraction.

Authors:  Mohammad Thawabi; Amer Hawatmeh; Sarah Studyvin; Habib Habib; Fayez Shamoon; Marc Cohen
Journal:  Cardiovasc Diagn Ther       Date:  2017-08

5.  Plasma cardiac troponin I concentration and cardiac death in cats with hypertrophic cardiomyopathy.

Authors:  K Borgeat; K Sherwood; J R Payne; V Luis Fuentes; D J Connolly
Journal:  J Vet Intern Med       Date:  2014-10-15       Impact factor: 3.333

6.  High-Sensitivity Cardiac Troponin: From Patient Phenotypes to Clinical Events in Patients With Heart Failure With Preserved Ejection Fraction.

Authors:  Biykem Bozkurt
Journal:  J Am Heart Assoc       Date:  2018-12-18       Impact factor: 5.501

Review 7.  Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond.

Authors:  Paolo Morfino; Alberto Aimo; Vincenzo Castiglione; Giuseppe Vergaro; Michele Emdin; Aldo Clerico
Journal:  J Cardiovasc Dev Dis       Date:  2022-08-10

Review 8.  Serelaxin: a novel therapy for acute heart failure with a range of hemodynamic and non-hemodynamic actions.

Authors:  Javier Díez
Journal:  Am J Cardiovasc Drugs       Date:  2014-08       Impact factor: 3.571

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.